What side effects are associated with this type of intervention?

Common treatments for Non-Hodgkin's Lymphoma, particularly those involving immune checkpoint inhibitors and monoclonal antibodies like CPI-006, can lead to a range of side effects. These include infusion reactions, which may present as fever, chills, and rash, and more severe immune-related adverse events such as pneumonitis, colitis, hepatitis, and endocrinopathies. Other side effects can include fatigue, nausea, diarrhea, and increased risk of infections due to immunosuppression. It is important for patients to discuss these potential side effects with their healthcare provider to manage and mitigate risks effectively.

What prior FDA approvals exist?

The FDA has approved several treatments for Non-Hodgkin's Lymphoma, including monoclonal antibodies and combination therapies. Rituximab, an anti-CD20 monoclonal antibody, is commonly used either alone or in combination with chemotherapy agents like bendamustine. Other approved monoclonal antibodies include obinutuzumab and ofatumumab. While specific CD73 inhibitors like CPI-006 are still under investigation, the use of monoclonal antibodies targeting different antigens on B cells has been a cornerstone in the treatment of NHL.

What other types of research exist?

Promising novel alternatives to CPI-006 for Non-Hodgkin's Lymphoma patients in 2024 include: 1) Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, which have shown efficacy in various subtypes of NHL. 2) BCL2 inhibitors like venetoclax, often used in combination with monoclonal antibodies such as obinutuzumab. 3) CAR T-cell therapies, including axicabtagene ciloleucel and tisagenlecleucel, which have shown promising results in relapsed or refractory NHL. 4) Bispecific T-cell engagers (BiTEs) like blinatumomab, which target CD19 on B-cells. These therapies represent significant advancements and offer new hope for NHL patients.

← Back to Search

Monoclonal Antibodies

CPI-006 Combinations for Advanced Cancer

Phase 1

Waitlist Available

Research Sponsored by Corvus Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial tests CPI-006, a protein that helps the immune system attack cancer cells, in adults with advanced cancers. It will be used alone and in combination with other treatments.

Who is the study for?

This trial is for adults with certain advanced cancers who have had limited prior treatments, can perform daily activities without significant assistance (ECOG 0-1), and have at least one measurable tumor. It's not for those with untreated brain metastases, severe reactions to monoclonal antibodies, recent investigational drug use, or specific immunotherapy-related side effects.

What is being tested?

The study tests CPI-006 alone and in combination with ciforadenant or pembrolizumab in patients with select advanced cancers. It's a Phase 1/1b trial aiming to find the right dose and see how safe and effective these combinations are against various cancer types.

What are the potential side effects?

Potential side effects may include typical reactions related to immune therapies such as inflammation of organs, infusion-related symptoms, allergic reactions similar to past monoclonal antibody treatments, fatigue, skin issues, and possibly pneumonitis.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups

Experimental Treatment

Group I: Cohort1bExperimental Treatment1 Intervention

CPI-006 + ciforadenant

Group II: Cohort 2cExperimental Treatment1 Intervention

CPI-006 + pembrolizumab

Group III: Cohort 2bExperimental Treatment1 Intervention

CPI-006 + ciforadenant

Group IV: Cohort 2aExperimental Treatment1 Intervention

CPI-006

Group V: Cohort 1cExperimental Treatment1 Intervention

CPI-006 + pembrolizumab

Group VI: Cohort 1aExperimental Treatment1 Intervention

CPI-006

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CPI-006 + pembrolizumab

2018

Completed Phase 1

~120

CPI-006

2018

Completed Phase 1

~150

CPI-006 + ciforadenant

2018

Completed Phase 1

~120

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Non-Hodgkin's Lymphoma (NHL) treatments often target specific molecules or pathways involved in cancer cell survival and proliferation. CD73 inhibitors like CPI-006 block the CD73 enzyme, reducing adenosine production and enhancing anti-tumor immune responses. Other common treatments include monoclonal antibodies such as rituximab, which targets the CD20 protein on B-cells, leading to their destruction. Chemotherapy agents like cyclophosphamide and doxorubicin disrupt DNA replication in rapidly dividing cells. Immune checkpoint inhibitors, such as pembrolizumab, block PD-1/PD-L1 interactions, reactivating T-cells to attack cancer cells. These mechanisms are crucial as they offer targeted approaches to eliminate cancer cells while sparing normal cells, improving treatment efficacy and reducing side effects for NHL patients.